Lindbrook Capital, LLC Uro Gen Pharma Ltd. Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$12.72 - $19.2 $928 - $1,401	-73 Reduced 45.63%	87 $1,000
Q1 2024 Apr 25, 2024	BUY	$13.81 - $19.33 $1,353 - $1,894	98 Added 158.06%	160 $2,000
Q4 2023 Jan 31, 2024	BUY	$10.87 - $15.93 $673 - $987	62 New	62 $0
Q4 2021 Jan 18, 2022	SELL	$9.03 - $19.13 $4,632 - $9,813	-513 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$14.31 - $18.39 $4,879 - $6,270	341 Added 198.26%	513 $9,000
Q2 2021 Jul 27, 2021	SELL	$15.2 - $20.94 $1,611 - $2,219	-106 Reduced 38.13%	172 $3,000
Q1 2021 Apr 28, 2021	SELL	$17.99 - $26.96 $1,403 - $2,102	-78 Reduced 21.91%	278 $5,000
Q4 2020 Jan 27, 2021	SELL	$17.54 - $25.43 $228 - $330	-13 Reduced 3.52%	356 $6,000
Q3 2020 Nov 03, 2020	SELL	$18.81 - $26.42 $2,276 - $3,196	-121 Reduced 24.69%	369 $7,000
Q2 2020 Jul 27, 2020	BUY	$16.5 - $29.7 $4,801 - $8,642	291 Added 146.23%	490 $13,000
Q1 2020 Apr 22, 2020	SELL	$13.68 - $34.6 $971 - $2,456	-71 Reduced 26.3%	199 $4,000
Q4 2019 Jan 27, 2020	BUY	$21.11 - $34.86 $5,699 - $9,412	270 New	270 $9,000

130

35.9M

22K

93.8K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $293M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.